AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33208658 — intervention group
Group type: EXPERIMENTAL
Intervention: Home biofeedback
Number of subjects: 54
Study 33208658 — intervention group
Group type: COMPARATOR
Intervention: PFPT
Number of subjects: 54
Study 32497023 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Arginine supplementation (0.05 mg/kg orally, twice daily)
Number of subjects: 50
Study 32497023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32497023 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Arginine supplementation
Number of subjects: 50
Study 35748393 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (10 mg, n=17)
Number of subjects: 51
Study 35748393 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride (200 mg, n=16)
Number of subjects: 51
Study 35748393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 51
Study 33901017 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 147
Study 33901017 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study 35319478 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based diabetes educational program (51 videos, 3 months duration, 2-3 videos/week, care messages every 2 weeks)
Number of subjects: 181
Study 35319478 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study 35319478 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based diabetes educational program
Number of subjects: 181
Study 34410410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) meal
Number of subjects: 21
Study 34410410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/high-fat (HPHF) meal
Number of subjects: 21
Study 34240571 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency (RF) treatment of the nasal valve
Number of subjects: 118
Study 34240571 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 118
Study 32101259 — intervention group
Group type: EXPERIMENTAL
Intervention: New LDL-C equation
Number of subjects: 8656
Study 35352499 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 0
Study 35352499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32129954 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam
Number of subjects: 426
Study 35593612 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education nursing skills (experimental group)
Number of subjects: 92
Study 35593612 — intervention group
Group type: COMPARATOR
Intervention: Traditional education model (control group)
Number of subjects: 92
Study 33069317 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 144
Study 33069317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144
Study 33069317 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144
Study 35819779 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS stimulation (anodal over left dorsolateral prefrontal cortex) for 13 consecutive days
Number of subjects: 49
Study 35819779 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 49
Study 35819779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tDCS and Sham)
Number of subjects: 49
Study 34049770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acetylcholine (ACh) injection
Number of subjects: 38
Study 32602830 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT-DH
Number of subjects: 114
Study 32602830 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT-IOP
Number of subjects: 114
Study 34174326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task with blood flow restriction (DTBFR)
Number of subjects: 24
Study 34174326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task (DT)
Number of subjects: 24
Study 34174326 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 24
Study 34252906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psychosocial interventions
Number of subjects: 0
Study 34252906 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger Adults (YA)
Number of subjects: 0
Study 32052468 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal speech condition
Number of subjects: 0
Study 32052468 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-salad condition
Number of subjects: 0
Study 32052468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-words condition
Number of subjects: 0
Study 32052468 — intervention group
Group type: COMPARATOR
Intervention: Control condition (spectrally rotated version of normal speech)
Number of subjects: 0
Study 34433510 — intervention group
Group type: EXPERIMENTAL
Intervention: CV + HIIT
Number of subjects: 46
Study 34433510 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + CV
Number of subjects: 46
Study 34433510 — intervention group
Group type: COMPARATOR
Intervention: CV
Number of subjects: 46
Study 33745757 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management, peer recovery coaching and overdose education and naloxone distribution (CM/PRC + OEND)
Number of subjects: 1000
Study 33745757 — intervention group
Group type: COMPARATOR
Intervention: Overdose education and naloxone distribution (OEND) alone
Number of subjects: 1000
Study 34923848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg
Number of subjects: 353
Study 34923848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: variant transthyretin amyloidosis)
Number of subjects: 353
Study 34923848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: wild-type transthyretin amyloidosis)
Number of subjects: 353
Study 34923848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: NYHA class I and II)
Number of subjects: 353
Study 34923848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 80 mg (subgroup: NYHA class III)
Number of subjects: 353
Study 34048027 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 4465
Study 34048027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4465
Study 34048027 — intervention group
Group type: COMPARATOR
Intervention: Combined analysis of anastrozole and exemestane
Number of subjects: 4465
Study 32113192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble-PEP
Number of subjects: 35
Study 32113192 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBT
Number of subjects: 35
Study 32113192 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 35505467 — intervention group
Group type: EXPERIMENTAL
Intervention: Keverprazan 20 mg once daily
Number of subjects: 238
Study 35505467 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 238
Study 35321130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot normobaric hypoxic (HH; 35℃, FiO2 14.5%)
Number of subjects: 9
Study 35321130 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxic (HYP; 23℃, FiO2 14.5%)
Number of subjects: 9
Study 35321130 — intervention group
Group type: COMPARATOR
Intervention: Normoxic (NOR; 23℃, 50%, FiO2 20.9%)
Number of subjects: 9
Study 35303958 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with Owner mask (NIV Owner COVID Group, n = 63)
Number of subjects: 383
Study 35303958 — intervention group
Group type: COMPARATOR
Intervention: NIV with conventional orofacial mask (NIV Orofacial COVID Group, n = 63)
Number of subjects: 383
Study 35303958 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with Owner mask (NIV Owner Non-COVID Group, n = 97)
Number of subjects: 383
Study 35303958 — intervention group
Group type: COMPARATOR
Intervention: NIV with conventional orofacial mask (NIV Orofacial Non-COVID Group, n = 97)
Number of subjects: 383
Study 35303958 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with Owner mask
Number of subjects: 383
Study 35303958 — intervention group
Group type: COMPARATOR
Intervention: NIV with conventional orofacial mask
Number of subjects: 383
Study 34311772 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min talocrural joint manual therapy plus 30-min specific task-oriented training (group A)
Number of subjects: 36
Study 34311772 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min specific task-oriented training (group B)
Number of subjects: 36
Study 34311772 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 36
Study 34311772 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 36
Study 36007166 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music during exercise
Number of subjects: 22
Study 33909360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment at Guanyuan (CV 4), Shuidao (ST 28), Guilai (ST 29), Shenshu (BL 23), and Ciliao (BL 32), disperse-dense wave, 2 Hz/15 Hz frequency, once a day for 10 days per menstrual cycle for 3 menstrual cycles
Number of subjects: 144
Study 33909360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 144
Study 33909360 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen sustained-release capsules, 0.3 g each time, once a day for 10 days before menstruation
Number of subjects: 144
Study 34142293 — intervention group
Group type: EXPERIMENTAL
Intervention: Various HIPEC regimens (specific regimens not detailed)
Number of subjects: 0
Study 34142293 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized medicine approaches (e.g., patient-derived tumor organoids)
Number of subjects: 0
Study 34142293 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert consensus on HIPEC regimens
Number of subjects: 0
Study 32009195 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (monoclonal antibody to IL-5) as an add-on therapy to glucocorticoid treatment
Number of subjects: 61
Study 32009195 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 61
Study 34235765 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Palliative Care Outcome Scale for people with dementia (IPOS-Dem)
Number of subjects: 0
Study 32354681 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered step count prescription
Number of subjects: 118
Study 35418065 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily contact testing (DCT) using a rapid Lateral Flow Device (LFD)
Number of subjects: 63
Study 35418065 — intervention group
Group type: COMPARATOR
Intervention: Self-isolation
Number of subjects: 63
Study 33570017 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (250 mg)
Number of subjects: 34
Study 33570017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32090430 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 1701129
Study 32090430 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 1701129
Study 32090430 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients (Control)
Number of subjects: 1701129
Study 32090430 — intervention group
Group type: COMPARATOR
Intervention: Type 1 Diabetes (T1D) vs Non-diabetic
Number of subjects: 1701129
Study 32090430 — intervention group
Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D) vs Non-diabetic
Number of subjects: 1701129
Study 35320555 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha® ointment (Lawsonia inermis 3 g and Curcuma longa 0.15 g/30 g), applied two times daily for 4 consecutive courses of chemotherapy
Number of subjects: 90
Study 35320555 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment, applied two times daily for 4 consecutive courses of chemotherapy
Number of subjects: 90
Study 35818363 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib in combination with remdesivir therapy (BCT)
Number of subjects: 891
Study 35818363 — intervention group
Group type: COMPARATOR
Intervention: Remdesivir monotherapy (RMT)
Number of subjects: 891
Study 32145827 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel plus ART
Number of subjects: 334
Study 32145827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide plus ART
Number of subjects: 334
Study 32145827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bleomycin and vincristine plus ART
Number of subjects: 334
Study 35751503 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroplasty group (GG; n = 39)
Number of subjects: 73
Study 35751503 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 34)
Number of subjects: 73
Study 33199052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 105
Study 33037803 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment with 1000 mg IV acetaminophen 20 min before surgery
Number of subjects: 120
Study 33037803 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment with 1000 mg IV acetaminophen after surgery
Number of subjects: 120
Study 33037803 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 120
Study 32171038 — intervention group
Group type: EXPERIMENTAL
Intervention: NDMC 20 mg
Number of subjects: 32
Study 32171038 — intervention group
Group type: EXPERIMENTAL
Intervention: NDMC 60 mg
Number of subjects: 32
Study 32171038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 1.5 mg
Number of subjects: 32
Study 32171038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32171038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 32
Study 32171038 — intervention group
Group type: EXPERIMENTAL
Intervention: NDMC
Number of subjects: 32
Study 34116817 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led navigation intervention (SHINE), two sessions
Number of subjects: 119
Study 34116817 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study 34116817 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led navigation intervention (SHINE)
Number of subjects: 119
Study 32353816 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based Mindfulness Intervention (FBMI)
Number of subjects: 51
Study 32353816 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 51
Study 615123829 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 6 liters per minute
Number of subjects: 42
Study 615123829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent mechanical ventilation (NIMV) at 12/5 cm H2O
Number of subjects: 42
Study 615123829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) at 5 cm H2O
Number of subjects: 42
Study 615123829 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) prior to extubation
Number of subjects: 42
Study 615123829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent mechanical ventilation (NIMV) with nasal clip
Number of subjects: 42
Study 35150473 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment
Number of subjects: 29
Study 33446307 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel PCI (MV‐PCI)
Number of subjects: 587
Study 33446307 — intervention group
Group type: COMPARATOR
Intervention: Culprit lesion–only PCI (CLO‐PCI)
Number of subjects: 587
Study 33446307 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (rSS)
Number of subjects: 587
Study 32442673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration (24 IU intranasally)
Number of subjects: 100
Study 32442673 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 100
Study 34382385 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1142
Study 34382385 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1142
Study 34654385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education resource focusing on liver cancer prevention
Number of subjects: 54
Study 34654385 — intervention group
Group type: COMPARATOR
Intervention: Standard HBV education package
Number of subjects: 54
Study 36319962 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripatellar plexus block (PP group)
Number of subjects: 50
Study 36319962 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FN group)
Number of subjects: 50
Study 33683465 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer (Hv-GIC)
Number of subjects: 56
Study 33683465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite
Number of subjects: 56
Study 35193640 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic discectomy
Number of subjects: 100
Study 35193640 — intervention group
Group type: COMPARATOR
Intervention: Microscopic discectomy
Number of subjects: 100
Study 34776475 — intervention group
Group type: EXPERIMENTAL
Intervention: Horseshoe osteotomy (HS)
Number of subjects: 40
Study 34776475 — intervention group
Group type: COMPARATOR
Intervention: LeFort I osteotomy (LF)
Number of subjects: 40
Study 35473589 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD prediction algorithm integrated into telehealth system
Number of subjects: 200
Study 34369696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiting (ST 44), Xiangu (ST 43), Dadu (SP 2), Taibai (SP 3), Zusanli (ST 36), etc. once every other day, 3 times a week for 4 weeks.
Number of subjects: 60
Study 34369696 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment only (Control group).
Number of subjects: 60
Study 34496300 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg intrauterine system (IUS) among women with heavy menstrual bleeding
Number of subjects: 6203
Study 34496300 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 52 mg intrauterine system (IUS) among users for contraception (comparison group)
Number of subjects: 6203
Study 34914334 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shenqi Dihuang Decoction (MSDD) + Maximal Androgen Blockade (MAB)
Number of subjects: 76
Study 34914334 — intervention group
Group type: COMPARATOR
Intervention: Maximal Androgen Blockade (MAB)
Number of subjects: 76
Study 34914334 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDD + MAB
Number of subjects: 76
Study 34775656 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic glasses during 4-week balance training
Number of subjects: 28
Study 34775656 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stroboscopic glasses)
Number of subjects: 28
Study 32414192 — intervention group
Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometers worn on non-dominant and dominant wrists, ankles, and waist during physical activity
Number of subjects: 20
Study 32414192 — intervention group
Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometers worn on dominant wrist, waist, non-dominant and dominant ankles
Number of subjects: 20
Study 32414192 — intervention group
Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometers worn on non-dominant wrist
Number of subjects: 20
Study 32414192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-points validated in the calibration
Number of subjects: 20
Study 36114901 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment
Number of subjects: 305
Study 35297472 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention targeting physical weakness, cognitive impairment, malnutrition, and anemia
Number of subjects: 0
Study 35297472 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient care
Number of subjects: 0
Study 32080973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vialon biomaterial catheter (BD Insyte™ Autoguard™ BC winged)
Number of subjects: 208
Study 32080973 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheter (BD Venflon™)
Number of subjects: 208
Study 32080973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vialon biomaterial catheter
Number of subjects: 208
Study 32080973 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheter
Number of subjects: 208
Study 36260832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) + Reirradiation (re-RT) 35 Gy in 10 fractions with concurrent BEV IV 10 mg/kg every 2 weeks
Number of subjects: 182
Study 36260832 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (BEV) alone
Number of subjects: 182
Study 34245667 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intra-ureteric stent (CIUS)
Number of subjects: 124
Study 34245667 — intervention group
Group type: COMPARATOR
Intervention: Conventional ureteric JJ stent (CUS)
Number of subjects: 124
Study 33917770 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Load Resistance Exercise (HL-RE)
Number of subjects: 43
Study 33917770 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Load Resistance Exercise (LL-RE)
Number of subjects: 43
Study 33031736 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention (n=64)
Number of subjects: 90
Study 33031736 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes management (Control group, n=26)
Number of subjects: 90
Study 33031736 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention (n=32 responders)
Number of subjects: 90
Study 33031736 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes management (Control group, n=13 non-responders)
Number of subjects: 90
Study 35428035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR)
Number of subjects: 63
Study 35428035 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 63
Study 33499543 — intervention group
Group type: EXPERIMENTAL
Intervention: Military Treatment Facility Engagement Committee (MTFEC)
Number of subjects: 0
Study 33499543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Management Collaboratory Coordinating Center (PMC3)
Number of subjects: 0
Study 33499543 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement strategies
Number of subjects: 0